Actinium Expands into Additional Offices in Metro Park in Edison, NJ to Support Growing Operations

New Offices will Sustain Development Activities Related to Iomab-B™ Phase 3, Actimab-A Phase 1/2 Clinical Trials and Pipeline Expansion

NEW YORK-- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, has added additional office space at 379 Thornall Street, Edison, NJ. The Company will continue to maintain its corporate headquarters in New York City.

The new offices are a key step towards supporting several corporate initiatives, including the advancement of the Companies lead clinical program Iomab™-B into a Phase 3 Pivotal trial and the ongoing Phase1/2 clinical programs for Actimab-A. In addition, they will support future growth opportunities as the Company advances existing earlier stage programs in other cancer indications.

Commenting on the expansion, Kaushik J. Dave, PhD., President and CEO of Actinium Pharmaceuticals said, “The new offices will enable Actinium to accelerate our efforts to build a strong, highly focused biotechnology company with an experienced management team that is well-positioned to successfully advance products from clinical development through commercialization. Our new location will support not only the recent expansion of our clinical, regulatory and pharmaceutical development staff but also the addition of new personnel as the advancement of our pipeline of innovative targeted payload immunotherapeutics including Iomab-B and Actimab-A continues.”

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. ( is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Actinium Pharmaceuticals, Inc.
Evan Smith, CFA, 646-840-5442
VP Investor Relations and Finance

Source: Actinium Pharmaceuticals, Inc.